Clinical validation of MYND Diagnostics’ proprietary biomarkers in evaluating the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression VANCOUVER, BC, Feb. 8, 2022 /CNW/ – MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF), is pleased to announce that the Company’s proprietary biomarker testing technology will be a pivotal…


Previous articleMydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada
Next articleCybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders